var data={"title":"Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes-A3","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes-A3</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/interactive-diabetes-case-17-a-57-year-old-woman-with-newly-discovered-type-2-diabetes-a3/contributors\" class=\"contributor contributor_credentials\">Lloyd Axelrod, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/interactive-diabetes-case-17-a-57-year-old-woman-with-newly-discovered-type-2-diabetes-a3/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 16, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">ANSWER</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Incorrect.</p><p>Sulfonylureas are effective agents for the treatment of newly diagnosed type 2 diabetes but are not indicated as initial pharmacologic therapy. (See <a href=\"topic.htm?path=initial-management-of-blood-glucose-in-adults-with-type-2-diabetes-mellitus\" class=\"medical medical_review\">&quot;Initial management of blood glucose in adults with type 2 diabetes mellitus&quot;</a>.)</p><p>Sulfonylureas reduce the glycated hemoglobin (A1C) to an extent comparable to <a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">metformin</a>, approximately 1.5 percent, but are associated with a weight gain of approximately 2 kg. Sulfonylureas carry the risk of hypoglycemia, especially the longer-lasting agents in older adults, although episodes of severe hypoglycemia (requiring the help of someone else) are infrequent. Among second-generation sulfonylureas (the preferred group of agents), <a href=\"topic.htm?path=glyburide-glibenclamide-drug-information\" class=\"drug drug_general\">glyburide</a> is more likely to cause hypoglycemia than <a href=\"topic.htm?path=glipizide-drug-information\" class=\"drug drug_general\">glipizide</a> or <a href=\"topic.htm?path=glimepiride-drug-information\" class=\"drug drug_general\">glimepiride</a>. Glyburide should not be used in patients with renal insufficiency (a serum creatinine &gt;1.5 <span class=\"nowrap\">mg/dL</span> in men or &gt;1.4 <span class=\"nowrap\">mg/dL</span> in women) because of the increased risk of hypoglycemia. Glipizide is preferred in this setting. (See <a href=\"topic.htm?path=sulfonylureas-and-meglitinides-in-the-treatment-of-diabetes-mellitus\" class=\"medical medical_review\">&quot;Sulfonylureas and meglitinides in the treatment of diabetes mellitus&quot;</a>.)</p><p>In a patient with a contraindication to <a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">metformin</a> because of preexistent gastrointestinal disease, or in a patient who does not tolerate a careful trial of metformin, a sulfonylurea such as <a href=\"topic.htm?path=glipizide-drug-information\" class=\"drug drug_general\">glipizide</a> is a reasonable alternative. While sulfonylureas are not the first choice for pharmacologic therapy of newly diagnosed diabetes, an agent in this class may have a role as an additional medication in patients who are not well controlled with one drug, usually metformin. (See <a href=\"topic.htm?path=management-of-persistent-hyperglycemia-in-type-2-diabetes-mellitus\" class=\"medical medical_review\">&quot;Management of persistent hyperglycemia in type 2 diabetes mellitus&quot;</a>.)</p><p>Return to the beginning to try again. (See <a href=\"topic.htm?path=interactive-diabetes-case-17-a-57-year-old-woman-with-newly-discovered-type-2-diabetes\" class=\"medical medical_review\">&quot;Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 4247 Version 5.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H1\" id=\"outline-link-H1\">ANSWER</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=initial-management-of-blood-glucose-in-adults-with-type-2-diabetes-mellitus\" class=\"medical medical_review\">Initial management of blood glucose in adults with type 2 diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=interactive-diabetes-case-17-a-57-year-old-woman-with-newly-discovered-type-2-diabetes\" class=\"medical medical_review\">Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-persistent-hyperglycemia-in-type-2-diabetes-mellitus\" class=\"medical medical_review\">Management of persistent hyperglycemia in type 2 diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sulfonylureas-and-meglitinides-in-the-treatment-of-diabetes-mellitus\" class=\"medical medical_review\">Sulfonylureas and meglitinides in the treatment of diabetes mellitus</a></li></ul></div></div>","javascript":null}